Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo

  • Medical Ophthalmology
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Previously, we have confirmed that the foldable capsular vitreous body (FCVB) can serve as a drug delivery system (DDS) as well as a vitreous substitute. Here, we evaluated the characteristics of the release of 5-fluorouracil (5-Fu) from FCVB in vitro and in vivo.

Methods

For the in-vitro study, various concentrations of 5-FU (50–200 μg/ml) were injected into FCVB capsules and immersed in cups of modified Franz diffusion cells, and liquid was aspirated at specific time intervals. In the in-vivo study, FCVB was folded and implanted into the vitreous cavity in the right eyes of five rabbits, and then 1.0 ml 5-Fu (200 μg/ml) was injected into the capsule. Another five rabbits that were used as the controls received intravitreal injections Aqueous humor was aspirated postoperatively at specific time intervals up to 56 days. The 5-Fu contents in vitro were detected by UV spectrophotometry and ultra performance liquid chromatography (UPLC), and the in-vivo 5-FU levels in the aqueous humour were detected by UPLC. The stock solution in the FCVB before-release study and the FCVB residue were collected for UPLC analysis.

Results

UV spectrophotometry revealed that 5-FU was released from FCVB in vitro in a time-dependent manner from 20–360 min in vitro. UPLC analysis revealed that 5-FU was released sustainably from FCVB. The 5-FU concentration in the aqueous humour was detected until postoperative day 56 (D56), with sustained release from postoperative days 3–56. However, the 5-FU concentration in the control samples was detected until only D7, and could not be detected on D14. Finally, 48.8% of the 5-FU was released on D56 in the in-vivo experiment.

Conclusions

FCVB can release 5-Fu sustainably and mechanically, indicating that FCVB can be used as a common vehicle for the sustainable release of different drugs. FCVB is a potentially valuable pharmaceutical adjunct to conventional vitreous surgery for managing or preventing proliferative vitreoretinopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Sunalp MA, Wiedemann P, Sorgente N, Ryan SJ (1985) Effect of adriamycin on experimental proliferative vitreoretinopathy in the rabbit. Exp Eye Res 41(1):105–115

    Article  PubMed  CAS  Google Scholar 

  2. Cowley M, Conway BP, Campochiaro PA, Kaiser D, Gaskin H (1989) Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol 107(8):1147–1151

    Article  PubMed  CAS  Google Scholar 

  3. Kirchhof B (2004) Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol 242(8):699–703

    Article  PubMed  CAS  Google Scholar 

  4. Azen SP, Scott IU, Flynn HW Jr, Lai MY, Topping TM, Benati L, Trask DK, Rogus LA (1998) Silicone oil in the repair of complex retinal detachments. A prospective observational multi center study. Ophthalmology 105:1587–1597

    Article  PubMed  CAS  Google Scholar 

  5. Bhisitkul RB, Gonzalez VH (2005) “Heavy oil” for intraocular tamponade in retinal detachment surgery. Br J Ophthalmol 89:649–650

    Article  PubMed  CAS  Google Scholar 

  6. Leone G, Consumi M, Aggravi M, Donati A, Lamponi S, Magnani A (2010) PVA/STMP based hydrogels as potential substitutes of human vitreous. J Mater Sci Mater 21:2491–2500

    Article  CAS  Google Scholar 

  7. Hong Y, Chirila TV, Vijayasekaran S, Shen W, Lou X, Dalton PD (1998) Biodegradation in vitro and retention in the rabbit eye of cross-linked poly (1-vinyl-2-pyrrolidinone) hydrogel as a vitreous substitute. J Biomed Mater Res 39:650–659

    Article  PubMed  CAS  Google Scholar 

  8. Wiedemann P, Heimann K (1986) Proliferative vitreoretinopathy: Pathogenesis and possibilities for treatment with cytostatic drugs. Klin Monatsbl Augenheilkd 188:559–564

    Article  PubMed  CAS  Google Scholar 

  9. Machemer R, Sugita G, Tano Y (1979) Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 77:171–180

    PubMed  CAS  Google Scholar 

  10. Giordano GG, Refojo MF, Arroyo MH (1993) Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest Ophthalmol Vis Sci 34:2743–2751

    PubMed  CAS  Google Scholar 

  11. Sonoda H, Enaida H, Ueno A, Nakamura T, Kawano Y-I, Kubota T, Sakamoto T, Ishibash T (2003) Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis: a case series study. Br J Ophthalmol 87(8):1010–1014

    Article  PubMed  Google Scholar 

  12. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG (2007) Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 114(4):698–704

    Article  PubMed  CAS  Google Scholar 

  13. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y (2004) Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 23(3):253–281

    Article  PubMed  CAS  Google Scholar 

  14. Colthurst MJ, Williams RL, Hiscott PS, Grierson I (2000) Biomaterials used in the posterior segment of the eye. Biomaterials 21(7):649–665

    Article  PubMed  CAS  Google Scholar 

  15. Liu Y, Ke Q, Chen J, Wang Z, Xie Z, Jiang Z, Ge J, Gao Q (2010) Sustained mechanical release of dexamethasone sodium phosphate from a foldable capsular vitreous body. Invest Ophthalmol Vis Sci 51(3):1636–1642

    Article  PubMed  Google Scholar 

  16. Lin X, Ge J, Gao Q, Wang Z, Long C, He L, Liu Y, Jiang Z (2011) Evaluation of the flexibility, efficacy, and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment. Invest Ophthalmol Vis Sci 52(1):374–381

    Article  PubMed  Google Scholar 

  17. Abraham LM, Selva D, Casson R, Leibovitch I (2007) The clinical applications of fluorouracil in ophthalmic practice. Drugs 67(2):237–255

    Article  PubMed  CAS  Google Scholar 

  18. Blumenkranz M, Hernandez E, Ophir A, Norton EW (1984) 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 91(2):122–3018

    PubMed  CAS  Google Scholar 

  19. Gao Q (2008) A novel method andomould for foldable capsular vitreous body. China patent No.200810199177

  20. Chen J, Gao Q, Liu Y, Ge J, Cao X, Luo Y, Huang D, Zhou G, Lin S, Lin J, To CH, Siu AW (2011) Evaluation of morphology and functions of a foldable capsular vitreous body in the rabbit eye. J Biomed Mater Res 97(2):396–404

    Article  Google Scholar 

  21. Jarus G, Blumenkranz M, Hernandez E, Sossi N (1985) Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology 92(1):91–96

    PubMed  CAS  Google Scholar 

  22. Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, Fisher SK (1983) Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol 96:43–51

    PubMed  CAS  Google Scholar 

  23. Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK, O’Donnell JJ (1983) Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol 96:33–42

    PubMed  CAS  Google Scholar 

  24. Rubsamen PE, Davis PA, Hernandez E, O'Grady GE, Cousins SW (1994) Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 112:407–413

    Article  PubMed  CAS  Google Scholar 

  25. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y (1991) Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci 32:1785–1790

    PubMed  CAS  Google Scholar 

  26. Peyman GA, Conway M, Khoobehi B, Soike K (1992) Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int Ophthalmol 16:109–111

    Article  PubMed  CAS  Google Scholar 

  27. Berger AS, Cheng CK, Pearson PA, Ashton P, Crooks PA, Cynkowski T, Cynkowska G, Jaffe GJ (1996) Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37(11):2318–2325

    PubMed  CAS  Google Scholar 

  28. Cardillo JA, Farah ME, Mitre J, Morales PH, Costa RA, Melo LAS (2004) An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 88(9):1201–1205

    Article  PubMed  CAS  Google Scholar 

  29. Joondcph BC, Khoobehi B, Peyman GA, Yue BY (1998) Liposome-encapsulatcd 5-fluorouracil in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg 19:252–256

    Google Scholar 

  30. Obmann A, Purevsuren S, Zehl M, Kletter C, Reznicek G, Narantuya S, Glasl S (2011) HPLC determination of flavonoid glycosides in Mongolian Dianthus versicolor Fisch. (Caryophyllaceae) compared with quantification by UV spectrophotometry. Phytochem Anal Sep 7 [Epub ahead of print]

  31. Liu Y, Jiang Z, Gao Q, Ge J, Chen J, Cao X, Shen Q, Ma P (2010) Technical standards of foldable capsular vitreous body regarding mechanical, optical and biocompatible properties. Artif Organs 34:836–845

    Article  PubMed  Google Scholar 

  32. Gao Q, Chen X, Ge J, Liu Y, Jiang Z, Lin Z, Liu Y (2009) Refractive shifts in four selected artificial vitreous substitutes based on Gullstrand-Emsley and Liou-Brennan schematic eyes. Invest Ophthalmol Vis Sci 50:3529–3534

    Article  PubMed  Google Scholar 

  33. Verstraeten TC, Buzney SM, Macdonald SG, Neufeld AH (1990) Retinal pigment epithelium wound closure in vitro. Pharmacologic inhibition. Invest Ophthalmol Vis Sci 31(3):481–488

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by the Project of Wenzhou Municipal Science and Technology Bureau in Zhejiang province (H20080029), Natural National Science Foundation of China (NSFC----30973258) and the National Basic Research Program of China (“973”program, Number 2007CB512200).

Conflict of interest

No conflicting relationship exists for any author.

Presentation at a conference

Rabbit, ARVO.

Author information

Authors and Affiliations

  1. The Second Affiliated Hospital of Wenzhou Medical College, 109 West Xueyuan Road, Wenzhou, 325000, China

    Haihua Zheng & Zhimin Wang

  2. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xianlie Road, Guangzhou, Guangdong, 510060, China

    Peijuan Wang, Yaqin Liu, Zhaoxin Jiang & Qianying Gao

Authors
  1. Haihua Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhimin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peijuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yaqin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhaoxin Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qianying Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Haihua Zheng.

Additional information

This manuscript has not been published or submitted for publication elsewhere. We certify that all applicable institutional and governmental regulations concerning the ethical use of human subjects were followed during this research. The authors have full control of the primary data, and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested. All authors equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zheng, H., Wang, Z., Wang, P. et al. Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol 250, 751–759 (2012). https://doi.org/10.1007/s00417-011-1862-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-011-1862-y

Keywords

Search

Navigation